Table 3.

Targetable Alterations and Their Corresponding ESCAT Tiers

ESCAT Tier	Molecular Target	Total Target Count (n = 274)	% of All Cohort Patients (n = 483)
IB	BRAFV600E	3	0.6
IIB	FGFR3 fusion	11	2.3
IIB	FGFR1 mutation	2	0.0
IIB	NTRK fusion	4	0.8
IIIA	CDK4/6 amplification	62	12.8
IIIA	EGFR mutation; intracellular domain	6	1.2
IIIA	HRD	7	1.4
IIIA	MET amplification	17	3.5
IIIA	MET fusion	1	0.2
IIIA	NF1 alteration	56	11.6
IIIA	PDGFRA amplification	42	8.7
IIIA	PDGFRA fusion	1	0.2
IIIA	TMB-high; pretreatment	4	0.8
IIIB	TMB-high; posttreatment	3	0.6
IIIB	TSC1 mutation	1	0.2
IV	MDM2/4-amp	54	11.2

The targets were selected and allocated to ESCAT tiers following the EANO guideline on rational molecular testing by Capper et al.⁹